AmgenAmgen Oncology

Amgen builds its oncology therapy-area portfolio on targeted small molecules, T-cell engager immunotherapies that direct the immune system to cancer cells, and monoclonal antibodies that target specific biomarkers.

The portfolio spans disease areas including blood cancers, lung cancer, gastrointestinal cancers such as colorectal and gastric cancer, prostate cancer, and solid tumors. Amgen also advances a differentiated clinical pipeline of oncology medicines.